Merck & Co. Inc., known as MSD outside the United States and Canada, reported a fall in profit for the fourth quarter, reflecting lower sales and one-time charges, while the prior-year quarter’s results were boosted by a hefty gain. However, adjusted earnings per share beat analysts’ expectations, while revenues missed their estimates.